Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1581-1600 of 1,694 trials

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Staphylococcus Aureus Bacteremia: Comparing Antibiotic Durations

We are studying whether 7 days of antibiotic treatment is as effective as 14 days for patients with uncomplicated Staphylococcus aureus bacteremia. This may help reduce antibiotic use and hospital stays.

Staphylococcus aureus Bacteremia≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Emergency Pain Relief: Sublingual Sufentanil Study

We are investigating whether sublingual sufentanil can effectively manage moderate to severe pain in emergency patients after a single trauma. The study will also assess safety and compare it to standard pain management methods.

Pain in Limb6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Chronic Heart Failure: Omecamtiv Mecarbil Study

We are testing a new medication for people with chronic heart failure and severely reduced heart function. The study aims to see if it can improve heart health outcomes compared to a placebo.

Heart Failure with Reduced Ejection Fraction>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Refractory Schizophrenia: NaBen® with Clozapine

We are studying whether NaBen®, a new medication, can help adults with refractory schizophrenia who still have symptoms despite treatment with clozapine. The trial will also assess the safety of this combination therapy.

Treatment-resistant Schizophrenia≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementPsychiatry

Glioblastoma Multiforme: Itraconazole with Radiotherapy and Temozolomide

We are studying whether adding Itraconazole to standard radiotherapy and temozolomide is safe for patients with newly diagnosed glioblastoma. Our goal is to find the best dose and understand its effects on survival and quality of life.

Glioblastoma≤3 monthsSafety phase (I)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Crohn's Disease in Children: Budesonide Treatment

We are studying a topical treatment with budesonide for children with Crohn's disease affecting the esophagus, stomach, or duodenum. The goal is to see if it helps reduce inflammation in these areas.

Crohn's Disease≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

Major Depressive Disorder: CYB003 Treatment Study

We are studying the effects of a new medication, CYB003, on symptoms of major depressive disorder in adults. This trial compares its effectiveness to a placebo to see if it may help improve mood and quality of life.

Major Depressive Disorder3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Cognitive Improvement in Down Syndrome: Bumetanide Study

We are investigating whether Bumetanide can enhance cognitive functions in children and adolescents with Down syndrome aged 10-16. This study aims to explore its effects on both thinking skills and related psychological aspects.

Down Syndrome>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPediatricsPsychiatry

IgA Nephropathy: Felzartamab Infusions

We are studying the effects of felzartamab infusions on adults with IgA nephropathy to see if it helps reduce protein in urine and improve kidney function compared to a placebo.

IgA Nephropathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

PCOS Fertility: Letrozole vs. Gonadotropins

We are studying whether continuing ovulation induction with letrozole is more effective than switching to gonadotropins for women with polycystic ovary syndrome. The trial also looks at safety, quality of life, and costs related to fertility treatment.

Polycystic Ovary Syndrome (PCOS)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and ObstetricsInternal Medicine

Personalized Treatment for High-Risk Breast Cancer: PETREMAC Trial

We are studying how personalized therapies can improve outcomes for patients with high-risk breast cancer. The trial looks at treatment responses and aims to enhance surgical options while ensuring safety.

Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alopecia Areata: Ritlecitinib Study

We are investigating whether two doses of ritlecitinib can help people aged 12 and older with alopecia areata regrow their scalp hair. The study compares the effects of the medication to a placebo.

Alopecia Areata6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Alzheimer's Disease: NPI-001 Study

We are testing a new oral medication, NPI-001, for people aged 50 to 85 with Mild Cognitive Impairment or mild dementia due to Alzheimer's. The study aims to assess its safety and effects on brain health and cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Blood Cancer Treatment: CCS1477 Study

We are testing the safety and effects of the experimental drug CCS1477 in patients with advanced blood and bone marrow cancers. This study aims to see how well it works alone and in combination with other treatments.

Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Multiple Myeloma (MM)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Solid Tumors: MK-5684 Study

We are testing a new treatment, MK-5684, for people with certain solid tumors to see if it helps them live longer without disease progression. The study also evaluates its safety and effectiveness compared to standard care.

Breast CancerOvarian CancerEndometrial Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Chronic Heart Failure: Combined Diuretic Therapy Study

We are comparing a new combined diuretic treatment to standard therapies for people with chronic heart failure. The goal is to see if it improves exercise capacity and fluid management.

Congestive Heart Failure>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Insomnia in Adolescents: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep in adolescents with psychiatric disorders and insomnia. We’ll also look at how these treatments affect overall well-being and daily functioning.

Psychiatric Disorders and Insomnia≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemotePsychiatry

WSD0922-FU for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment for patients with advanced NSCLC who have a specific mutation and did not respond to prior therapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology